• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

    1/17/23 8:00:00 AM ET
    $AGRX
    $GNTA
    $NMTR
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGRX alert in real time by email

    Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management.

    During his tenure at BDSI, Mark was responsible for creating and overseeing the implementation of the company's corporate strategy and overseeing all business operations. Additionally, Mark executed on the development, NDA approval, and commercialization of three products in neurological and pain indications, Onsolis®, Bunavail®, and Belbuca®. BDSI was successfully sold to Collegium Pharmaceutical, Inc. in March 2022.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch indicated for the treatment of mild, moderate, and severe dementia in Alzheimer's patients.

    Mark joins Corium Pharma Solutions shortly after its formation in October 2022, when Webster Equity Partners ("Webster") acquired the standalone business unit from its former, commercial-stage biopharmaceutical parent company, Corium. Corium's original investor, Gurnet Point Capital ("Gurnet Point"), remains as a joint owner in Corium Pharma Solutions and each Gurnet Point and Webster have equal board representation.

    "I am thrilled to welcome Mark as Chief Executive Officer of Corium Pharma Solutions," said Travis Wilson, Partner at Gurnet Point. "Mark's decades of industry experience and proven track record of research, development, and commercialization of pharmaceutical products make him the ideal leader for the next phase of Corium Pharma Solutions' growth. He is uniquely qualified to step into the leadership role and Corium Pharma Solutions will benefit from his deep product development, regulatory, and commercial experience across numerous therapeutics areas."

    "I am excited to have the opportunity to lead the Corium Pharma Solutions team as we continue to build on the company's historical successes and further establish its leadership position in transdermal contract development and manufacturing," said Dr. Mark Sirgo, Chief Executive Officer. "With the backing and financial support of Gurnet Point and Webster, I look forward to focusing on both supporting our current partners and procuring new business opportunities within our current capabilities, while selectively adding to our breadth of specialty offerings through M&A to extend our commercial product footprint."

    Prior to founding BDSI, Mark was Senior Vice President, Global Business Development at PPD, Inc., where he managed global sales and marketing for one of the world's largest contract research organizations serving biopharmaceutical, pharmaceutical, and device industries. Further, he held several leadership positions at GSK plc in clinical development and marketing and was a Director at Salix Pharmaceuticals, Ltd. prior to its sale to Valeant Pharmaceuticals International, Inc. in 2015. Mark also currently serves as Chairman of 9 Meters Biopharma, Inc. (NASDAQ:NMTR) and Genenta Science SpA (NASDAQ:GNTA).

    Dr. Sirgo holds a PharmD from Philadelphia College of Pharmacy and Sciences, and a BS in Pharmacy from The Ohio State University.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Pharma Solutions offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by Gurnet Point Capital and Webster Equity Partners.

    About Gurnet Point Capital

    Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005355/en/

    Get the next $AGRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $GNTA
    $NMTR
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    7/25/2025$170.00Overweight → Neutral
    Analyst
    Procter & Gamble Company
    $PG
    7/14/2025$170.00Outperform → In-line
    Evercore ISI
    Procter & Gamble Company
    $PG
    5/1/2025$161.00Buy → Neutral
    Redburn Atlantic
    Procter & Gamble Company
    $PG
    4/25/2025$177.00Sector Perform → Outperform
    RBC Capital Mkts
    Procter & Gamble Company
    $PG
    11/25/2024$160.00 → $209.00Neutral → Buy
    DA Davidson
    Procter & Gamble Company
    $PG
    10/10/2024$159.00Neutral
    DA Davidson
    Procter & Gamble Company
    $PG
    9/30/2024$163.00Overweight → Equal Weight
    Barclays
    Procter & Gamble Company
    $PG
    9/24/2024$174.00Neutral
    Piper Sandler
    More analyst ratings

    $AGRX
    $GNTA
    $NMTR
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iconic Laundry Care Brand, Bounce, Unveils New Bounce Intense Dryer Sheets With Freshness That Lasts For Up To Four Weeks

    NEW Bounce Intense infuses clothes with long-lasting freshness, leveraging innovative heat-activated technology that bursts with movement Bounce, the leading dryer sheet brand from Procter & Gamble, is resetting laundry expectations with the introduction of Bounce Intense, a multi-benefit dryer sheet engineered to deliver 10x the freshness of a leading base dryer sheet*. Launched in September 2025, Bounce Intense not only offers the static and wrinkle control that is a hallmark of the brand, but also provides the ultimate fresh experience that bursts from the dryer and lasts through wear for up to four weeks. This press release features multimedia. View the full release here: https://www

    9/29/25 9:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G to Webcast Discussion of First Quarter 25/26 Earnings Results on October 24

    The Procter & Gamble Company (NYSE: PG) will webcast a discussion of its first quarter earnings results on Friday, October 24, 2025, beginning at 8:30 a.m. ET. Media and investors may access the live audio webcast at www.pginvestor.com. The webcast will also be available for replay. About Procter & Gamble P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately

    9/26/25 12:00:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    All Roads Lead to Oz: Olay Body and Secret Unveil Limited-Edition Wicked: For Good Collection

    Olay Body and Secret join forces with Universal Pictures for new line-up of body washes and deodorants inspired by the epic conclusion to the global cinematic Wicked sensation Universal Pictures' Wicked: For Good Arrives in Theaters November 21, 2025. Olay Body and Secret are transforming your body care routine from mundane to magical with the new Wicked: For Good collection, available for a limited-time only. Inspired by the captivating worlds of the witches of Oz, Elphaba and Glinda, this hydrating collection features serum-infused body washes and clinical strength deodorants formulated with superior skincare technology and enchanting scents. The collection is available for purchase t

    9/25/25 10:53:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Human Resources Officer Purushothaman Balaji

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    9/17/25 9:35:48 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Chief Operating Officer Jejurikar Shailesh

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    9/17/25 9:34:33 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    9/17/25 9:32:43 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Procter & Gamble downgraded by Analyst with a new price target

    Analyst downgraded Procter & Gamble from Overweight to Neutral and set a new price target of $170.00

    7/25/25 9:00:02 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Procter & Gamble from Outperform to In-line and set a new price target of $170.00

    7/14/25 8:41:25 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble downgraded by Redburn Atlantic with a new price target

    Redburn Atlantic downgraded Procter & Gamble from Buy to Neutral and set a new price target of $161.00

    5/1/25 7:44:23 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    SEC Filings

    View All

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    9/25/25 12:17:03 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    9/25/25 12:14:17 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    9/24/25 1:05:28 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Leadership Updates

    Live Leadership Updates

    View All

    IFF Appoints Virginia "Gina" Drosos to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served

    6/9/25 5:46:00 PM ET
    $IFF
    $PG
    $SIG
    Major Chemicals
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Appoints Craig Arnold to Board of Directors

    The Procter & Gamble Company (NYSE:PG) today announced the appointment of Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, to its Board of Directors, effective June 9, 2025. Mr. Arnold brings significant experience as a successful chief executive of a global enterprise serving businesses and customers in more than 175 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609584955/en/P&G Appoints Craig Arnold to Board of Directors With a distinguished career at Eaton, a global leader in power infrastructure and technology, Arnold led the company through transformative changes from 2016 to Ma

    6/9/25 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

    Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

    1/8/25 3:17:00 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $GNTA
    $NMTR
    $PG
    Financials

    Live finance-specific insights

    View All

    P&G Announces Fourth Quarter and Fiscal Year 2025 Results

    Q4 '25: Net Sales +2%; Organic Sales +2%; Diluted EPS +17%; Core EPS +6% FY '25: Net Sales 0%; Organic Sales +2%; Diluted EPS +8%; Core EPS +4% The Procter & Gamble Company (NYSE:PG) reported fourth quarter and fiscal year 2025 results. "We grew sales and profit in fiscal 2025 and returned high levels of cash to shareowners in a dynamic, difficult and volatile environment," said Jon Moeller, Chairman of the Board, President and Chief Executive Officer. "We've put in place strong plans to continue to deliver for all stakeholders in the current environment. In fiscal 2026, we expect to deliver another year of organic sales growth, Core EPS growth and strong adjusted free cash flow produ

    7/29/25 7:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Shailesh Jejurikar Elected P&G President and Chief Executive Officer

    Jon Moeller to Become Executive Chairman The Procter & Gamble Company (NYSE:PG) announced today that Shailesh Jejurikar, currently Chief Operating Officer, will succeed Jon Moeller as Procter & Gamble's President and Chief Executive Officer, effective January 1, 2026. The Board has also nominated Mr. Jejurikar to stand for election as a Director at the annual shareholder meeting in October 2025. On January 1, 2026, Jon Moeller will become Procter & Gamble's Executive Chairman. In this role, Mr. Moeller will lead the Board of Directors and provide advice and counsel to the CEO on Company matters. This press release features multimedia. View the full release here: https://www.businesswire.

    7/28/25 5:00:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Declares Quarterly Dividend for July 2025

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after August 15, 2025 to Common Stock shareowners of record at the close of business on July 18, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on July 18, 2025. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, many of who

    7/8/25 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $GNTA
    $NMTR
    $PG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/22/24 4:50:46 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/9/24 2:20:54 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/2/24 3:44:23 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care